Daniele Raggi
@danieleraggi83
Locum Consultant in Genito-Urinary oncology @RoyalMarsdenNHS
ID: 912051838463168512
24-09-2017 20:31:18
143 Tweet
356 Followers
798 Following
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit: Cancer Cell cell.com/cancer-cell/fu… Our review on neoadjuvant immune checkpoint therapy is out. Kristen E Pauken Omar Alhalabi, MD Pam Sharma MD Anderson Cancer Center
We tested the feasibility and immunogenicity of a personalized neoantigen vaccine + PD-L1 blockade in #bladdercancer including the adjuvant setting. nature.com/articles/s4301… Jon Anker, MD, PhD Bhardwaj Lab UroToday.com Uromigos The Tisch Cancer Institute Dr. Bishoy M. Faltas Nature Cancer Bladder Cancer Advocacy Network
Thank you #ESTRO25! ✅Presented my proffered paper on an international stage ✅Shortlisted for an ESTRO Young Researcher Award ✅ Ranked in the top 5% of all abstracts! 🙏🏽 to all my multidisciplinary colleagues, mentors & collaborators #VincentKhoo The Royal Marsden NHS Foundation Trust #ICR UK Early Career Researchers in Cancer (UK ECRC)💡
🧬 Thanks to Margaret Ottaviano for the invitation to “Second Mediterranean Conference: Embracing Cancer Immunotherapy” 💉Stay hungry, don't stop learning, be inspired by the energy of research, don't stop dreaming that we can do even more! Congrats to all! OncoDaily IO OncoAlert
Join us in Lisbon early December for a wonderful meeting how to apply data in clinic across GU cancers! Mirrors of Medicine Prof Ananya💙 @achoud72.bsky.social Badrinath Konety, MD, MBA Paul Sargos silke gillessen Marc-Olivier Timsit, MD, PhD 🎗️ Pedro C Barata, MD MSc FACP Marinos Tsiatas ANASTASIOS KYRIAZOGLOU Myrto K. Moutafi Bernadett Szabados Manuela Schmidinger OncoAlert Daniele Raggi
Congratulations Daniele Raggi & team JCO Oncology Practice great work indeed! See you soon in Chicago! Robert Huddart💙 Walter Cazzaniga
Just in The Lancet Oncology The PROs from the EV-302 trial, which led to the global approval of 1L EV+pembro in mUC 👉EV+P led to clinically meaningful pain relief, esp. in pts with moderate-severe baseline pain 👉EV+P led to better EORTC QLQ-C30 functioning and QoL improvements
Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology Full-text authors.elsevier.com/a/1lFrI3lXQoc1… Harshani Green 💙 @harshanigreen.bsky.social Alison Tree 💙 The Royal Marsden NHS Foundation Trust The ICR Elsevier Oncology Advance
Why attend #RENALC25, #BLADDR25 and #PROSCA25? Hear it straight from Vérane Achard in this quick video 👇 ➡️ Register now: tinyurl.com/mryx8kwe 💎Dive into the clinical application of new GU oncology data 👥 Learn from multidisciplinary experts 🗓️3-6 December 2025 | 📍
🔵 NEW #WoW in European Urology by Daniele Raggi Does extended lymphadenectomy (eLND) improve outcomes in MIBC? 📉 No DFS or OS benefit vs standard LND ⚠️ More severe AEs & perioperative deaths 🚫 Time to shift focus: better systemic therapy, not bigger surgery. 🧠
Great work Daniele Raggi Deep Chakrabarti Robert Huddart💙! Was a pleasure to be part of this piece alongside my wonderful colleagues The Royal Marsden NHS Foundation Trust
Delighted to share our comprehensive review on #ProstateCancer, now out in CA: A Cancer Journal for Clinicians , the highest-impact STEM journal. Huge thanks to an amazing team ! Alison Tree 💙 Chris Parker Amar Kishan Vedang Murthy Nicholas van As The Royal Marsden NHS Foundation Trust The ICR Link: doi.org/10.3322/caac.7…
🧵1/ 🚨 Just out in Science Translational Medicine Science Translational Medicine our latest work Luigi NALDINI: We show how tumor-targeted cytokines can rescue CAR-T function and recruit endogenous T cells to fight glioblastoma, the toughest brain cancer. 🔗science.org/doi/10.1126/sc… 👇 Here's a thread:
Minimizing Toxicity From Chemotherapy in Early-Stage Testicular Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/OP… Thank you Christopher Wee, MD Cleveland Clinic MD Cleveland Clinic IM For the excellent review OncoAlert
